Tag: Sarepta Therapeutics

Sarepta Therapeutics finds itself navigating significant regulatory challenges as the U.S. Food and Drug Administration has imposed the most serious ...

Sarepta Therapeutics experienced one of its most severe trading sessions in recent history, with shares collapsing by more than 33%. ...

Investors in Sarepta Therapeutics are approaching the company's upcoming quarterly report with heightened anticipation. The biotech firm's shares recently climbed ...

Institutional investors are demonstrating significant confidence in Sarepta Therapeutics through recent strategic moves. Privium Fund Management B.V. established a new ...

Sarepta Therapeutics shares continue to experience extreme volatility as promising clinical developments clash with significant safety concerns. The biotechnology firm ...

Sarepta Therapeutics witnessed a dramatic trading session as its stock price jumped more than 10%, closing at $21.32 before extending ...

Sarepta Therapeutics shares advanced 3.6% to $18.72 in the latest trading session, yet this modest gain conceals a deeply fractured ...

Sarepta Therapeutics shares closed Friday's trading session down 2.9 percent at $17.39, a decline that occurred despite a positive earnings ...

Sarepta Therapeutics finds itself at a pivotal crossroads as it transitions from the S&P MidCap 400 to the S&P SmallCap ...

Biotechnology firm Sarepta Therapeutics is confronting the most severe crisis in its corporate history. A combination of regulatory rejections for ...